All Products

Support

All Products | Copper State Research

Cu Glow Anti-Aging Serum (30mL)

• Advanced Peptide and Exosome Technology for Visible Renewal Turn back the clock on tired, dull skin with Cu GLOW Anti-Aging Serum—a scientifically advanced formula designed to deliver rejuvenation, hydration, and radiance. This next-generation serum blends Glow Peptides, Tri-Phase Hyaluronic Acid, and Exotropin Exosomes to visibly firm, smooth, and renew skin texture. Engineered for daily use, it helps restore elasticity and a luminous glow while defending against visible signs of aging at the cellular level. • Tri-Phase Hyaluronic Acid Complex This multi-weight hydration system penetrates multiple layers of the skin to replenish moisture, restore suppleness, and deliver a visibly smoother texture with lasting hydration. • eXo™ Exosome Technology Powered by next-generation Exotropin Exosomes, this advanced delivery system enhances cellular communication and renewal, promoting visibly smoother, more radiant skin. • Copper Tripeptide-1 Integration This clinically recognized peptide supports collagen and elastin synthesis while enhancing antioxidant defenses—helping to maintain firmness, resilience, and a youthful-looking complexion. • Synergistic Hydration and Elasticity Profile Formulated with a precision-engineered blend of active peptides and humectants, the serum improves moisture retention, enhances elasticity, and refines overall tone to reveal a lifted, revitalized appearance. • Optimized for Daily Use Lightweight, fast-absorbing, and suitable for all skin types, Cu GLOW Anti-Aging Serum integrates seamlessly into any skincare regimen—delivering results that look as vibrant as they feel. Relevant Research Ye, C., Zhang, Y., Su, Z., Wu, S., Li, Y., Yi, J., Lai, W., Chen, J., & Zheng, Y. (2022). hMSC exosomes as a novel treatment for female sensitive skin: An in vivo study. Frontiers in Bioengineering and Biotechnology, 10. https://doi.org/10.3389/fbioe.2022.1053679 Ingredients: Water, Methyl Gluceth-20, Bis-PEG-18 Methyl Ether Dimethyl Silane, Sodium Hyaluronate, Sodium Acetylated Hyaluronate, Sodium Hyaluronate Crosspolymer, Hydrolyzed Sodium Hyaluronate, Human Adipose Stromal Cell Exosome, Sclerotium Gum,_Copper Tripeptide-1, Aloe Barbadensis Leaf Extract, Allantoin, Cholecalciferol, Retiny| Palmitate, Morinda Citrifolia Fruit Juice, Tocopheryl Acetate, Phytic Acid, Glycerin, Algae Extract, Chondrus Crispus Extract, Propanediol, Agastache Mexicana Flower/Leaf/Stem Extract, Undaria Pinnatifida Extract, Laminaria Digitata Extract, Ulva Lactuca (Sea Lettuce) Extract, Citric Acid, Sodium Hydroxide, Caprylyl Glycol, Hexylene Glycol, Phenoxyethanol, Ethylhexylglycerin.

Tesofensine (250mcg) / Dihexa (10mg) x 60 Tablets

• Composition and format Tesofensine (250 mcg) / Dihexa (10 mg) is a fixed-combination research formulation supplied as solid-format tablets for controlled laboratory workflows. Each tablet contains 250 mcg of tesofensine and 10 mg of dihexa, with 60 tablets per container. The batch-specific Certificate of Analysis (COA) documents active-component identities, per-tablet content verification, physical characteristics, and relevant excipient information to support reproducibility, mass-balance calculations, and documentation control in research environments. • Analytical verification Each production lot is qualified at 99%+ purity by high-performance liquid chromatography, with compound identities confirmed by mass spectrometry. Independent third-party laboratories corroborate in-house analytical results to maintain traceable quality metrics appropriate for research use. • Intended research use Tesofensine / Dihexa is evaluated exclusively in controlled in-vitro systems investigating monoaminergic signaling dynamics, neurotrophic pathway modulation, and synaptic signaling models under defined assay conditions. All technical communications are method-centric and do not imply diagnostic, therapeutic, performance, or clinical outcomes in humans or animals. • Research characteristics and applications This multi-analyte formulation is characterized for use as a research tool in analytical and cell-based models examining interactions between neurotransmitter reuptake modulation and hepatocyte growth factor–related signaling pathways. In controlled in-vitro environments, researchers employ the formulation to study synaptic signaling behavior, receptor- and transporter-associated responses, neuroplasticity-related pathway activation, and pathway cross-talk between small-molecule and peptide-mimetic components. Representative applications include assay development, comparative concentration-response profiling, time-course analyses, and mechanistic investigations of neurochemical signaling strictly within laboratory settings. • Manufacturing and documentation Alpha BioMed Labs manufactures this material in the United States under defined quality procedures and research-only labeling. Certificates of Analysis, raw-material sourcing from vetted suppliers, and complete batch documentation are maintained to support institutional procurement review, traceability, and audit readiness. Research Use Only (RUO) Statement • For in-vitro research only • Not for human or animal consumption • Not for diagnostic or therapeutic use

$255.00

Methblue (25mg) / Methylliberine (50mg) x 60 Tablets

• Composition and format Methblue (25 mg) / Methylliberine (50 mg) x 60 Tablets is a fixed-combination research formulation supplied as solid-format tablets for controlled laboratory workflows. Each tablet contains 25 mg of methylene blue and 50 mg of methylliberine, with 60 tablets per container. The batch-specific Certificate of Analysis (COA) details active-component identities, per-unit content, physical form, and relevant excipient information, supporting method-level reproducibility, mass-balance calculations, and documentation control in research environments. • Analytical verification Each lot is qualified at 99%+ purity by high-performance liquid chromatography; identity is confirmed by mass spectrometry; and independent third-party laboratories corroborate in-house analytics to maintain traceable quality metrics appropriate for research use. • Intended research use Methblue (25 mg) / Methylliberine (50 mg) is evaluated in controlled in-vitro systems interrogating mitochondrial redox cycling, electron-transport-associated pathways, and neuroactive signaling models, including studies of monoamine- and adenosine-associated mechanisms under defined assay conditions. All technical communications are method-centric and do not imply diagnostic, therapeutic, performance, or clinical outcomes in humans or animals. • Research characteristics and applications This combination of methylene blue and methylliberine is characterized for use as a multi-analyte research tool in analytical and cell-based models examining redox modulation, cellular energy-related signaling, and neurochemical pathway mapping. In defined in-vitro environments, researchers employ the formulation to study electron-transfer dynamics, changes in cellular redox state, receptor- and transporter-level responses, second-messenger generation, and interaction networks between redox-active and neuroactive systems. Representative applications include assay development, comparative profiling of concentration-response relationships, time-course analyses, and mechanistic studies of mitochondrial and signaling-pathway behavior strictly within laboratory settings. • Manufacturing and documentation Alpha BioMed Labs manufactures this material in the United States under defined quality procedures and research-only labeling. COAs, raw-material provenance from vetted suppliers, and batch records are maintained to facilitate institutional procurement review and audit readiness. Research Use Only (RUO) Statement • For in-vitro research only • Not for human or animal consumption • Not for diagnostic or therapeutic use

$200.00

Brain Blend - Dihexa (10mg) / Tesofensine (250mcg) / BPC-157 (125mcg) x 60 Tablets

• Composition and format Brain Blend - Dihexa (10 mg) / Tesofensine (250 mcg) / BPC-157 (125 mcg) x 60 Tablets is a fixed-combination research formulation supplied as solid-format tablets for controlled laboratory workflows. Each tablet contains 10 mg of Dihexa, 250 mcg of Tesofensine, and 125 mcg of BPC-157, with 60 tablets per container. The batch-specific Certificate of Analysis (COA) details compound identities, per-unit content, physical form, and relevant excipient information, supporting method-level reproducibility, mass-balance calculations, and documentation control in research settings. • Analytical verification Each lot is qualified at 99%+ purity by high-performance liquid chromatography; identity is confirmed by mass spectrometry; and independent third-party laboratories corroborate in-house analytics to maintain traceable quality metrics appropriate for research use. • Intended research use This Brain Blend is evaluated in controlled in-vitro systems investigating multi-target signaling, including neuroactive pathway models, energy-balance-related neurotransmitter systems, and peptide-mediated cell-communication networks, as well as pathway mapping in complex assay designs. All technical communications are method-centric and do not imply diagnostic, therapeutic, performance, or clinical outcomes in humans or animals. • Research characteristics and applications This combination of Dihexa, Tesofensine, and BPC-157 is characterized for use as a multi-analyte research reagent in analytical and cell-based models. Researchers employ the blend in defined in-vitro environments to examine concentration-response relationships, receptor and transporter engagement, downstream signaling cascades, and interaction networks among neuroactive and peptide pathways. Applications include comparative pathway profiling, assay development, and systems-level mapping of molecular feedback loops under controlled laboratory conditions only. • Manufacturing and documentation Alpha BioMed Labs manufactures this material in the United States under defined quality procedures and research-only labeling. COAs, raw-material provenance from vetted suppliers, and batch records are maintained to facilitate institutional procurement review and audit readiness. Research Use Only (RUO) Statement • For in-vitro research only • Not for human or animal consumption • Not for diagnostic or therapeutic use

$349.00

BPC-157 (500mcg) x 30 Tablets

• Composition and format BPC-157 (500 mcg) is a synthetic pentadecapeptide supplied as 500 mcg per tablet, with 30 tablets per container for controlled laboratory workflows using solid-format test articles. The batch-specific Certificate of Analysis (COA) details peptide identity, peptide content per unit, physical form, and relevant excipient information, supporting method-level reproducibility, mass-balance calculations, and documentation control in research environments. • Analytical verification Each lot is qualified at 99%+ purity by high-performance liquid chromatography; identity is confirmed by mass spectrometry; and independent third-party laboratories corroborate in-house analytics to maintain traceable quality metrics appropriate for research use. • Intended research use BPC-157 (500 mcg) is evaluated in controlled in-vitro systems investigating peptide-mediated signaling, including models focused on extracellular matrix regulation, cellular stress-response pathways, and related signal-transduction networks in defined assay platforms. All technical communications are method-centric and do not imply diagnostic, therapeutic, performance, or clinical outcomes in humans or animals. • Research characteristics and applications This synthetic peptide is characterized for use as a research reagent in analytical and cell-based models examining peptide-dependent modulation of signaling cascades, matrix-associated processes, and downstream molecular feedback loops. Researchers employ BPC-157 (500 mcg) in defined in-vitro environments to study concentration-response relationships, pathway activation profiles, and interaction networks at the cellular and molecular level, strictly within laboratory assay designs and not in any in-vivo context. • Manufacturing and documentation Alpha BioMed Labs manufactures this material in the United States under defined quality procedures and research-only labeling. COAs, raw-material provenance from vetted suppliers, and batch records are maintained to facilitate institutional procurement review and audit readiness. Research Use Only (RUO) Statement • For in-vitro research only • Not for human or animal consumption • Not for diagnostic or therapeutic use

$95.00

Thymalin (20mg)

• Composition and format Thymalin (20 mg) is a peptide complex supplied as a lyophilized powder in a single vial. Each vial contains 20 mg of Thymalin. The batch-specific Certificate of Analysis (COA) provides peptide characterization data, molecular profile verification, and formulation details to support method-level reproducibility and documentation control in research environments. • Analytical verification Each lot is qualified at 99%+ purity by high-performance liquid chromatography; molecular identity and integrity are confirmed by mass spectrometry. Independent third-party laboratories corroborate in-house analytical results to maintain traceable quality metrics appropriate for research use. • Intended research use Thymalin is evaluated exclusively in controlled in-vitro systems investigating immune-associated signaling pathways, thymic peptide–related cellular communication, and gene-expression modulation models under defined assay conditions. All technical communications are method-centric and do not imply diagnostic, therapeutic, performance, or clinical outcomes in humans or animals. • Research characteristics and applications Thymalin is characterized as a peptide-based research material utilized in analytical and cell-based models examining immune signaling dynamics, cellular differentiation processes, and regulatory pathway interactions. In controlled in-vitro environments, researchers employ Thymalin to study cytokine-associated signaling behavior, transcriptional modulation patterns, and concentration-response relationships relevant to immune-system pathway mapping. Representative applications include assay development, mechanistic pathway investigations, time-course analyses, and cellular signaling characterization strictly within laboratory settings. • Manufacturing and documentation Alpha BioMed Labs manufactures this material in the United States under defined quality procedures and research-only labeling. Certificates of Analysis, raw-material sourcing from vetted suppliers, and complete batch documentation are maintained to support institutional procurement review, traceability, and audit readiness. Research Use Only (RUO) Statement • For in-vitro research only • Not for human or animal consumption • Not for diagnostic or therapeutic use

$110.00

LL-37 (10mg)

• Composition and format LL-37 (10 mg) is a synthetic antimicrobial peptide supplied as a lyophilized powder in a single vial. Each vial contains 10 mg of LL-37. The batch-specific Certificate of Analysis (COA) provides peptide sequence confirmation, molecular weight verification, and formulation details to support method-level reproducibility and documentation control in research environments. • Analytical verification Each lot is qualified at 99%+ purity by high-performance liquid chromatography; peptide identity and molecular integrity are confirmed by mass spectrometry. Independent third-party laboratories corroborate in-house analytical results to maintain traceable quality metrics appropriate for research use. • Intended research use LL-37 is evaluated exclusively in controlled in-vitro systems examining innate immune signaling, antimicrobial peptide–mediated cellular interactions, and host-defense pathway models. All technical communications are method-centric and do not imply diagnostic, therapeutic, performance, or clinical outcomes in humans or animals. • Research characteristics and applications LL-37 is characterized by a defined amino-acid sequence and reproducible physicochemical properties relevant to peptide–membrane interaction studies. In controlled in-vitro environments, researchers employ LL-37 to investigate membrane-disruption dynamics, immune signaling modulation, inflammatory pathway activation, and cellular stress-response mechanisms. Representative applications include assay development, mechanistic pathway analysis, comparative concentration-response studies, and modeling of innate immune system interactions strictly within laboratory settings. • Manufacturing and documentation Alpha BioMed Labs manufactures this material in the United States under defined quality procedures and research-only labeling. Certificates of Analysis, raw-material sourcing from vetted suppliers, and complete batch documentation are maintained to support institutional procurement review, traceability, and audit readiness. Research Use Only (RUO) Statement • For in-vitro research only • Not for human or animal consumption • Not for diagnostic or therapeutic use

$100.00

Kisspeptin (5mg)

• Composition and format Kisspeptin (5 mg) is a synthetic research peptide supplied as 5 mg per vial for controlled laboratory workflows. The batch-specific Certificate of Analysis (COA) details peptide identity, sequence information, net peptide content, and physical state (e.g., lyophilized solid), supporting method-level reproducibility and documentation control in research environments. • Analytical verification Each lot is qualified at 99%+ purity by high-performance liquid chromatography; identity is confirmed by mass spectrometry; and independent third-party laboratories corroborate in-house analytics to maintain traceable quality metrics appropriate for research use. • Intended research use Kisspeptin (5 mg) is evaluated in controlled in-vitro systems interrogating kisspeptin-receptor (KISS1R/GPR54) signaling, including models examining GnRH neuron activation, hypothalamic-pituitary-gonadal (HPG) axis-related pathway mapping, and neuroendocrine communication networks. All technical communications are method-centric and do not imply diagnostic, therapeutic, performance, or clinical outcomes in humans or animals. • Research characteristics and applications This peptide is characterized for use as a research reagent in analytical and cell-based models studying kisspeptin-dependent signaling cascades and upstream regulation of GnRH-associated pathways. Researchers employ Kisspeptin (5 mg) in defined in-vitro environments to examine ligand-receptor interactions, receptor activation kinetics, downstream kinase and transcriptional responses, and network-level feedback loops within neuroendocrine and endocrine-model systems. These applications are limited to controlled laboratory assays and mechanistic studies rather than any in-vivo or performance-directed context. • Manufacturing and documentation Alpha BioMed Labs manufactures this material in the United States under defined quality procedures and research-only labeling. COAs, raw-material provenance from vetted suppliers, and batch records are maintained to facilitate institutional procurement review and audit readiness. Research Use Only (RUO) Statement • For in-vitro research only • Not for human or animal consumption • Not for diagnostic or therapeutic use

$70.00

BPC-157 (5mg)

• Composition and format BPC-157 (5 mg) is a synthetic pentadecapeptide supplied as 5 mg per vial for controlled laboratory workflows. The batch-specific Certificate of Analysis (COA) details peptide identity, net peptide content, format (e.g., lyophilized state), and relevant excipient or counterion information where applicable, supporting method-level reproducibility, experimental standardization, and documentation control in research environments. • Analytical verification Each lot is qualified at 99%+ purity by high-performance liquid chromatography; identity is confirmed by mass spectrometry; and independent third-party laboratories corroborate in-house analytics to maintain traceable quality metrics appropriate for research use. • Intended research use BPC-157 is evaluated in controlled in-vitro systems investigating peptide-mediated signaling events, including models focused on cellular stress responses, extracellular matrix regulation, and angiogenesis-related pathway mapping. All technical communications are method-centric and do not imply diagnostic, therapeutic, performance, or clinical outcomes in humans or animals. • Research characteristics and applications This synthetic peptide is characterized for use as a research reagent in analytical and cell-based models studying peptide-dependent modulation of signaling cascades, matrix-associated processes, and related molecular feedback loops. Researchers employ BPC-157 in defined in-vitro environments to examine concentration-response relationships, pathway activation profiles, and interaction networks at the cellular and molecular level, strictly within laboratory assay designs. • Manufacturing and documentation Alpha BioMed Labs manufactures this material in the United States under defined quality procedures and research-only labeling. COAs, raw-material provenance from vetted suppliers, and batch records are maintained to facilitate institutional procurement review and audit readiness. Research Use Only (RUO) Statement • For in-vitro research only • Not for human or animal consumption • Not for diagnostic or therapeutic use

$55.00

BPC-157 (10mg) Acetylated

• Composition and format BPC-157 (10 mg) Acetylated is a synthetic pentadecapeptide analog supplied as 10 mg per vial for controlled laboratory workflows. The batch-specific Certificate of Analysis (COA) details peptide identity, acetylation status, net peptide content, format (e.g., lyophilized state), and any relevant counterion or excipient information, supporting method-level reproducibility and documentation control. • Analytical verification Each lot is qualified at 99%+ purity by high-performance liquid chromatography; identity is confirmed by mass spectrometry; and independent third-party laboratories corroborate in-house analytics to maintain traceable quality metrics appropriate for research use. • Intended research use BPC-157 (10 mg) Acetylated is evaluated in controlled in-vitro systems investigating peptide-mediated signaling, including models focused on angiogenesis-related pathways, extracellular matrix regulation, and cellular stress-response mechanisms, as well as pathway mapping in complex assay designs. All technical communications are method-centric and do not imply diagnostic, therapeutic, performance, or clinical outcomes in humans or animals. • Research characteristics and applications This acetylated synthetic peptide is characterized for use as a research reagent in analytical and cell-based models examining peptide-dependent modulation of signaling cascades, matrix-associated processes, and downstream molecular feedback loops. Researchers employ BPC-157 (10 mg) Acetylated in defined in-vitro environments to study concentration-response behavior, pathway activation profiles, and interaction networks at the cellular and molecular level, strictly within laboratory assay designs. • Manufacturing and documentation Alpha BioMed Labs manufactures this material in the United States under defined quality procedures and research-only labeling. COAs, raw-material provenance from vetted suppliers, and batch records are maintained to facilitate institutional procurement review and audit readiness. Research Use Only (RUO) Statement • For in-vitro research only • Not for human or animal consumption • Not for diagnostic or therapeutic use

$75.00

BPC-157 (10mg)

• Composition and format BPC-157 (10 mg) is a synthetic pentadecapeptide supplied as 10 mg per vial for controlled laboratory workflows. The batch-specific Certificate of Analysis (COA) details peptide identity, net peptide content, format (e.g., lyophilized state), and any relevant excipient or counterion information, supporting method-level reproducibility, experimental standardization, and documentation control in research environments. • Analytical verification Each lot is qualified at 99%+ purity by high-performance liquid chromatography; identity is confirmed by mass spectrometry; and independent third-party laboratories corroborate in-house analytics to maintain traceable quality metrics appropriate for research use. • Intended research use BPC-157 is evaluated in controlled in-vitro systems investigating peptide-mediated signaling, including models focused on angiogenesis-related pathways, extracellular matrix regulation, and cellular stress-response mechanisms. All technical communications are method-centric and do not imply diagnostic, therapeutic, performance, or clinical outcomes in humans or animals. • Research characteristics and applications This synthetic peptide is characterized for use as a research reagent in analytical and cell-based models examining peptide-dependent modulation of signaling cascades, matrix-associated processes, and related molecular feedback loops. Researchers employ BPC-157 in defined in-vitro environments to study concentration-response relationships, pathway activation profiles, and interaction networks at the cellular and molecular level, strictly within laboratory assay designs and without any in-vivo context. • Manufacturing and documentation Alpha BioMed Labs manufactures this material in the United States under defined quality procedures and research-only labeling. COAs, raw-material provenance from vetted suppliers, and batch records are maintained to facilitate institutional procurement review and audit readiness. Research Use Only (RUO) Statement • For in-vitro research only • Not for human or animal consumption • Not for diagnostic or therapeutic use

$75.00

BDNF (Brain-derived neurotrophic factor) (10mg)

• Composition and format BDNF (Brain-Derived Neurotrophic Factor) (10 mg) is a recombinant neurotrophin-class peptide supplied as 10 mg per vial for controlled in-vitro research workflows. Batch-specific Certificates of Analysis (COAs) document identity, net peptide content, counterion information where applicable, and physical state (e.g., lyophilized solid), supporting method development, internal documentation, and reproducibility across experiments. • Analytical verification Each lot is qualified at 99%+ purity by high-performance liquid chromatography; identity is confirmed by mass spectrometry; and independent third-party laboratories corroborate in-house analytics to maintain traceable quality metrics appropriate for research use. • Intended research use BDNF is supplied for in-vitro research applications investigating neurotrophin-associated signaling pathways, receptor-ligand interactions, and downstream molecular responses in controlled experimental systems. All technical communications are method-centric and do not imply diagnostic, therapeutic, performance, or clinical outcomes in humans or animals. • Research characteristics and applications In cell and molecular biology settings, BDNF is incorporated into defined in-vitro models to examine parameters such as TrkB receptor engagement, signal transduction cascades, transcriptional responses, and network-level pathway mapping in neuronal and related cell types. Researchers may use this material to characterize concentration-response behavior, compare pathway activation profiles, or support assay development where a well-characterized neurotrophin standard is required. Any reference to cellular or molecular effects pertains exclusively to controlled laboratory systems rather than to in-vivo or human use contexts. • Manufacturing and documentation Alpha BioMed Labs manufactures this material in the United States under defined quality procedures and research-only labeling. COAs, raw-material provenance from vetted suppliers, and batch records are maintained to facilitate institutional procurement review and audit readiness. Research Use Only (RUO) Statement • For in-vitro research only • Not for human or animal consumption • Not for diagnostic or therapeutic use

$150.00